Cytodyn Inc Quick Ratio (CYDY) starting from the fourth quarter 2026 to fourth quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cytodyn inc   (CYDY)

Cytodyn Inc 's Quick Ratio

CYDY's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2026, Quick Ratio fell to 0.22 below Cytodyn Inc average.

Within Major Pharmaceutical Preparations industry 416 other companies have achieved higher Quick Ratio than Cytodyn Inc in fourth quarter 2026. While Quick Ratio total ranking has improved so far during the Q4 2026 to 3082, from total ranking in the third quarter 2026 at 4504.

Explain Quick Ratio?
How much Cash & cash equivalents CYDY´s has?
What are CYDY´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CYDY Quick Ratio (May 31 2026)
Q4		 (Feb 28 2026)
Q3		 (Nov 30 2025)
Q2		 (Aug 31 2025)
Q1		 (May 31 2025)
Q4
Y / Y Current Liabilities Change -23.81 % -28.54 % 3.37 % -0.2 % -16.23 %
Y / Y Cash & cash equivalent Change -0.43 % -4.54 % 282.73 % -62.55 % 282.73 %
Quick Ratio MRQ 0.22 0.31 0.14 0.13 0.17
CYDY's Total Ranking # 3082 # 4504 # 4315 # 4225 # 3953
Seq. Current Liabilities Change 6.54 % -42.05 % 25.36 % -1.56 % -0.07 %
Seq. Cash & cash equivalent Change -24.29 % 31.52 % 27.55 % -21.6 % -27.42 %



Quick Ratio fourth quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 417
Healthcare Sector # 816
Overall Market # 3314


Quick Ratio Statistics
High Average Low
4.27 0.55 0.01
(Feb 29 2016)   (Feb 29 2024)




Financial Statements
Cytodyn Inc 's Current Liabilities $ 54 Millions Visit CYDY's Balance sheet
Cytodyn Inc 's Cash & cash equivalent $ 12 Millions Visit CYDY's Balance sheet
Source of CYDY's Sales Visit CYDY's Sales by Geography


Cumulative Cytodyn Inc 's Quick Ratio

CYDY's Quick Ratio for the trailling 12 Months

CYDY Quick Ratio

 (May 31 2026)
12 Months		 (Feb 28 2026)
12 Months		 (Nov 30 2025)
12 Months		 (Aug 31 2025)
12 Months		 (May 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth -11.61 % -10.08 % -19.02 % -26.88 % -36.26 %
Y / Y Cash & cash equivalent TTM Growth -13.48 % 2.63 % 52.21 % 27.42 % 519.8 %
Quick Ratio TTM 0.19 0.18 0.17 0.14 0.19
Total Ranking TTM # 4091 # 2199 # 1663 # 2560 # 390
Seq. Current Liabilities TTM Growth -6.05 % -6.77 % 0.96 % -0.05 % -4.43 %
Seq. Cash & cash equivalent TTM Growth -0.1 % -1.5 % 21.58 % -27.67 % 18.5 %

Quick ratio ranking by company, industry and sector >> Back to CYDY Financial Strength Comparisons >> Go to Compare CYDY Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Cytodyn Inc 's average Cash & cash equivalent, this led to increase in in Cytodyn Inc 's Quick Ratio to 0.19, Quick Ratio remained below CYDY average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 442 other companies have achieved higher Quick Ratio than Cytodyn Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2026 from 2199 to 4091.

Explain Quick Ratio?
How much Cash & cash equivalents CYDY´s has?
What are CYDY´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 443
Healthcare Sector # 908
Within the Market # 4091


trailing twelve months Quick Ratio Statistics
High Average Low
2.5 0.39 0.02
(Nov 30 2016)  




Companies with similar Quick Ratio in the quarter ending May 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMay 31 2026 MRQ Cash & cash equivalentMay 31 2026 MRQ Current Liabilities
Eton Pharmaceuticals Inc   0.59 $ 26.845  Millions$ 45.124  Millions
Kura Oncology Inc   0.59 $ 70.242  Millions$ 118.193  Millions
Allarity Therapeutics Inc   0.59 $ 16.982  Millions$ 28.579  Millions
Bristol myers Squibb Company  0.59 $ 11,067.000  Millions$ 18,659.000  Millions
Prestige Consumer Healthcare Inc   0.58 $ 89.127  Millions$ 153.806  Millions
Biora Therapeutics Inc   0.57 $ 21.906  Millions$ 38.687  Millions
Matinas Biopharma Holdings Inc   0.56 $ 0.761  Millions$ 1.350  Millions
Karyopharm Therapeutics Inc   0.56 $ 75.225  Millions$ 134.233  Millions
Journey Medical Corp  0.56 $ 25.643  Millions$ 45.770  Millions
Nektar Therapeutics  0.55 $ 39.267  Millions$ 70.985  Millions
Supernus Pharmaceuticals inc   0.52 $ 180.145  Millions$ 347.378  Millions
Citius Oncology Inc  0.50 $ 16.564  Millions$ 33.152  Millions
Verrica Pharmaceuticals Inc   0.50 $ 11.198  Millions$ 22.442  Millions
Aytu Biopharma Inc  0.48 $ 26.308  Millions$ 54.659  Millions
Jupiter Neurosciences Inc   0.47 $ 1.522  Millions$ 3.251  Millions
Aeon Biopharma inc   0.47 $ 3.431  Millions$ 7.342  Millions
Evolus Inc   0.46 $ 45.170  Millions$ 98.731  Millions
Biomarin Pharmaceutical Inc  0.45 $ 874.005  Millions$ 1,927.164  Millions
Pds Biotechnology Corp  0.45 $ 5.596  Millions$ 12.377  Millions
Biofrontera Inc   0.44 $ 4.659  Millions$ 10.541  Millions
Beyondspring Inc   0.43 $ 10.361  Millions$ 23.834  Millions
Organon and Co   0.43 $ 1,132.000  Millions$ 2,616.000  Millions
Gossamer Bio Inc   0.41 $ 57.026  Millions$ 137.783  Millions
Bausch Health Companies Inc   0.39 $ 1,825.000  Millions$ 4,687.000  Millions
Johnson and Johnson  0.38 $ 21,094.000  Millions$ 54,895.000  Millions
Ultragenyx Pharmaceutical Inc   0.36 $ 125.000  Millions$ 351.000  Millions
Vanda Pharmaceuticals Inc   0.34 $ 56.119  Millions$ 164.026  Millions
Ainos Inc   0.29 $ 1.423  Millions$ 4.928  Millions
Elanco Animal Health Incorporated  0.29 $ 530.000  Millions$ 1,852.000  Millions
Provectus Biopharmaceuticals Inc   0.27 $ 1.157  Millions$ 4.234  Millions

Date modified: 2026-09-05T08:54:17+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.